The Medical University of Lublin has started a clinical research directed to patients with myasthenia. The project received a grant of PLN 26 million under the first competition of the Medical Research Agency for research and development.

Myasthenia gravis is an autoimmune disease of the group of neuromuscular diseases involving the disturbance of neuromuscular transmission. As a result of excessive activation of the immune system, it forms abnormal antibodies, which leads to muscle weakness.

Prof. Konrad Rejdak, author of this innovative project developed at the Medical University of Lublin, used cladribine in the treatment of patients with myasthenia gravis as an original therapeutic method worldwide.

The pilot study showed the high effectiveness of the new method. Its results have been published in the European Journal of Neurology and the journal Nature.